Displaying 49 - 60 of 183
Viral Hepatitis
5

Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023

View
Viral Hepatitis
5

Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023

View
Viral Hepatitis
5

Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023

View
Viral Hepatitis
3

Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” - EASL Congress 2023

View
Viral Hepatitis
3

Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
5

GSK: "Investigating IBAT inhibition in itch – a new tool for an age-old problem?" - EASL Congress 2023

View
Displaying 49 - 60 of 183